Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2020

View Archived Issues

scRNA-seq of Trypanosoma brucei from tsetse reveals candidates for a transmission-blocking vaccine

Anti-IL-1b platelet conjugate prevents sterile inflammation and adverse cardiac remodeling after AMI

Positive data for RECCE-327 in models of kidney and UTI infection

Sihuan Pharmaceutical initiates phase III study of anaprazole sodium in duodenal ulcer

GeneTx receives approval to initiate phase I/II study GTX-102

Phase I data presented for fosciclopirox in advanced solid tumors

Bayer presents data from phase II/III FORT-1 study of rogaratinib

Preliminary data presented from POLARIS-03 study of toripalimab in UC

Hinova Pharmaceuticals discovers new BRD4 inhibitors

High affinity nerve growth factor receptor inhibitors presented by JC Pharma

New IDO-1 inhibitors identified at Bristol-Myers Squibb

Domain Therapeutics patents mGluR4 positive allosteric modulators

Dual mu-opioid/voltage-gated calcium channels alpha2/delta-1 subunit ligands synthesized at Esteve

Ebola survivor's antibodies reveal therapeutic targets

Origin story helps ovarian cancer prognosis

Kinase, caspase play unexpected roles in NASH

MAO-A inhibitor phenelzine shows promise for treating recurrent prostate cancer

Phase I preliminary data presented for ACTUS-101 in late-onset Pompe disease

The Year's New Drugs & Biologics reviews 2019's new drugs and candidates for 2020 approval

FDA approves Twirla contraceptive patch

Beovu approved in E.U. for wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...